6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors

Future Medicinal Chemistry

Volumn 2, Issue 7, 2010, Pages 1161-1180

  Tabarrini, Oriana ^a   Massari, Serena ^a   Cecchetti, Violetta ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENYLQUINOLONE DERIVATIVE; 26 C; 26 I; 6 AMINO 1,4 DIHYDRO 1 METHYL 7 [4 (2 PYRIDYL) 1 PIPERAZINYL] 4 OXO 3 QUINOLINECARBOXYLIC ACID; 6 AMINOQUINOLONE; 6 DESFLUOROQUINOLONE DERIVATIVE; AMINOGLYCOSIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; CIPROFLOXACIN; CYCLIN DEPENDENT KINASE INHIBITOR; ELVITEGRAVIR; FLAVOPIRIDOL; HM 12; HM 13; HM 13 N; JTK 101; NAPHTHALENE DERIVATIVE; NEOMYCIN; PROCHLORPERAZINE; PROMAZINE; QUINOLONE DERIVATIVE; RITONAVIR; ROSCOVITINE; RUFLOXACIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WM 14; WM 16; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOTOXICITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS LATENCY;

ANIMALS; ANTI-HIV AGENTS; FLUOROQUINOLONES; HIV INFECTIONS; HIV-1; HUMANS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION, GENETIC;

EID: 77954688186     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.208     Document Type: Review

References (111)

1. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J. Allergy Clin. Immunol. 122(1), 22-28 (2008).
2. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Res. 6(5), 388-400 (2008).
3. Marsden MD, Zack JA. Eradication of HIV: current challenges and new directions. Antimicrob. Chemother. 63(1), 7-10 (2009).
4. Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V. Resistance to novel drug classes. Curr. Opin. HIV AIDS4(6), 531-537 (2009).
5. Hamer DH. Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it. Curr. HIVRes. 2(2), 99-111 (2004).
6. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6:111. DOI: 10.1186/1742-4690-6-111 (2009) (Epub ahead of print).
7. Demonte D, Quivy V, Colette Y, Van Lint C. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem. Pharmacol. 68(6), 1231-1238 (2004).
8. Reuse S, Calao M, Kabeya K et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 4(6), e6093 (2009).
9. Savarino A, Mai A, Norelli S et al. 'Shock and kill' effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 6(52). DOI: 10.1186/1742-4690-6-52 (2009) (Epub ahead of print).
10. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J. 17(23), 7056-7065 (1998).
11. Karn J. Tackling Tat. J. Mol. Biol. 293(2), 235-254 (1999).
12. Marcello A, Zoppe M, Giacca M. Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. IUBMB Life 51(3), 175-181 (2001).
13. Stevens M, De Clercq E, Balzarini J. The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. J. Med. Res. Rev. 26(5), 595-625 (2006).
14. Peterlin PM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell23(3), 297-305 (2006).
15. Faris MA, Raasch RH, Hopfer RL, Butts JD. Treatment and prophylaxis of disseminated Mycobacterium avium complex in HIV-infected individuals. Ann. Pharmacother. 32(5), 564-573 (1998).
16. Cecchetti V, Fravolini A, Fringuelli R et al. Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3- de][1,4] benzothiazine-6-carboxylic acids. J. Med. Chem. 30(3), 465-473 (1987).
17. Cecchetti V, Clementi S, Cruciani G et al. 6-aminoquinolones: a new class of quinolones antibacterials? J. Med. Chem. 38(6), 973-982 (1995).
18. Cecchetti V, Fravolini A, Lorenzini MC, Tabarrini O, Terni P, Xin T. Studies on 6-aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-methylquinolones. J. Med. Chem. 39(2), 436-445 (1996).
19. Cecchetti V, Fravolini A, Palumbo M et al. Potent 6-desfluoro-8- methylquinolones as new lead compounds in antibacterial chemotherapy. J. Med. Chem. 39(25), 4952-4957 (1996).
20. Wise R, Pagella PG, Cecchetti V, Fravolini A, Tabarrini O. In vitro activity of MF 5137, a new potent 6-aminoquinolone. Drugs 49(2), 272-273 (1995).
21. Nozaki-Renard J, Iino T, Sato Y, Maremoto Y, Ohta G, Furusawa M. Fluoroquinolones protect the human lymphocyte CEM line from HIV-1 mediated cytotoxicity. Cell Struct. Funct. 15(5), 295-299 (1990).
22. Nozaki-Renard J, Iino T, Sato Y, Maremoto Y, Ohta G, Furusawa M. A fluoroquinolone (DR3355) protects human lymphocyte cell lines from HIV-1 induced cytotoxicity. AIDS 4(12), 1283-1286 (1990).
23. Gollapudi S, Kim CH, Roshanravan B, Gupta S. Ciprofloxacin inhibits activation of latent human immunodeficiency virus type 1 in chronically infected promonocytic U1 cells. AIDS Res. Human Retrovirus 14(6), 499-504 (1998).
24. Cruciani G, Fravolini A, Cecchetti V et al. Quinolones as anti-HIV agents. Presented at: XII Convegno Nazionale Divisione di Chimica Farmaceutica SCI. Paestum, Italy, 23-27 September 1996.
25. Cecchetti V, Parolin C, Moro S et al. 6-aminoquinolones as new potential anti-HIV agents. J. Med. Chem. 43(20), 3799-3802 (2000).
26. Parolin C, Gatto B, Del Vecchio C et al. New anti-human immunodeficiency type 1 6-aminoquinolones: mechanism of action. Antimicrob. Agents Chemother. 47(3), 889-895 (2003).
27. Thomas JR, Hergenrother PJ. Targeting RNA with small molecules. Chem Rev. 108(4), 1171-1224 (2008).
28. Aboul-Ela F. Strategies for the design of RNA-binding small molecules. Future Med. Chem. 2(1), 93-119 (2010).
29. Richter S, Parolin C, Gatto B et al. Inhibition of human immunodeficiency virus type 1 Tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob. Agents Chemother. 48(5), 1895-1899 (2004).
30. Manfroni G, Gatto B, Tabarrini O et al. Synthesis and biological evaluation of 2-phenylquinolones targeted as Tat/TAR recognition. Bioorg. Med. Chem. 19(3), 714-717 (2009).
31. Tabarrini O, Stevens M, Checchetti V et al. Structure modification of 6-aminoquinolones with potent anti-HIV activity. J. Med. Chem. 47(22), 5567-5578 (2004).
32. Tabarrini O, Massari S, Daelemans D et al. Structure-activity relationship study on anti-HIV 6-desfluoroquinolones. J. Med. Chem. 51(17), 5454-5458 (2008).
33. Massari S, Daelemans D, Manfroni G et al. Studies on anti-HIV quinolones: new insights on the C-6 position. Bioorg. Med. Chem. 17(2), 667-674 (2009).
34. Massari S, Daelemans D, Barreca ML et al. A 1,8-naphthyridone derivative targets the HIV-1 Tat-mediated transcription and potently inhibits the HIV-1 replication. J. Med. Chem. 53(2), 641-648 (2010).
35. Tabarrini O, Cecchetti V, Massari S, et al. 6-Desfluoroquinolones as promising HIV transcription inhibitors. Presented at: International Symposium on Advances in Synthetic and Medicinal Chemistry.
36. Filipponi E, Cruciani G, Tabarrini O, Cecchetti V, Fravolini A. 3D-QSAR study of anti-HIV quinolone library. J. Comp. Aid. Mol. Des. 15(3), 203-217 (2001).
37. Stevens M, Pollicita M, Pannecouque C et al. A novel in vivo model for the study of HIV-1 transcription inhibitors: evaluation of new 6-desfluoroquinolones derivatives (6-DFQs). Antimicrob. Agents Chemother. 5(4), 1407-1413 (2007).
38. Mitscher LA, Devasthale P, Zavod R. Structure-activity relationships. In Quinolone Antimicrobial Agents (2nd Edition). Hooper DC, Wolfson JS (Eds.). American Society for Microbiology. Washington DC, USA, 3-51 (1998).
39. Richter S, Parolin C, Palumbo M, Palu G. Antiviral properties of quinolone-based drugs. Curr. Drug Targets Infect. Disor. 4(2), 111-116 (2004).
40. Baba M, Okamoto M, Makino M et al. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 41(6), 1250-1255 (1997). (Pubitemid 27231422)
41. Hagihara M, Kashiwase H, Katsube T et al. Synthesis and anti-HIV activity of arylpiperazinyl fluoroquinolones: a new class of anti-HIV agents. Bioorg. Med. Chem. Lett. 9(21), 3063-3068 (1999).
42. Stevens M, Balzarini J, Lagoja IM et al. Inhibition of human immunodeficiency virus type 1 transcription by N-aminoimidazole derivatives. Virology 365(1), 220-237 (2007).
43. Stevens M, Balzarini J, Tabarrini O et al. Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. J. Antimicrob. Chemother. 56(5), 847-855 (2005).
44. Sorbera LA, Serradell N. GS9137. Drugs Fut. 31(4), 310-313 (2006).
45. Nair V, Chi G. HIV integrase inhibitors as therapeutic agents in AIDS. Rev. Med. Virol. 17(4), 277-295 (2007).
46. Daelemans D, Lu R, De Clercq E, Engelman A. Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/ simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors. J. Virol. 81(8), 4381-4385 (2007).
47. Richter S, Gatto B, Tabarrini O, Fravolini A, Palumbo M. Antiviral 6-aminoquinolones: molecular basis for potency and selectivity. Bioorg. Med. Chem. Lett. 15(19), 4247-4251 (2005).
48. Mercorelli B, Muratore G, Sinigalia E et al. A 6-aminoquinolone compound, WC5, with potent and selective anti-human cytomegalovirus activity. Antimicrob. Agents Chemother. 53(1), 312-315 (2009).
49. Loregian A, Mercorelli B, Muratore G et al. The 6-aminoquinolone compound WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral IE2 protein. J. Antimicrob. Chemother. 54(5), 1930-1940 (2010).
50. Brideau RJ, Knechtel ML, Huang A et al. Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res. 54(1), 19-28 (2002).
51. Oien NL, Brideau RJ, Hopkins TA et al. Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob. Agents Chemother. 46(3), 724-730 (2002).
52. Mehellou Y, De Clercq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J. Med. Chem. 53 (2), 521-538 (2010).
53. Baba M. Recent status of HIV-1 gene expression inhibitors. Antiviral Res. 71(2-3), 301-306 (2006).
54. Al-Mawsawi LQ, Neamati N. Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy. Trends Pharmacol. Sci. 28(10), 526-535 (2007).
55. Khattab MA. Targeting host factors: a novel rationale for the management of hepatitis C virus. World J. Gastroenterol. 15(28), 3472-3479 (2009).
56. Rice AP, Sutton RE. Targeting protein-protein interactions for HIV therapeutics. Futur. HIV Ther. 1(3), 369-385 (2007).
57. Ludwig S. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J. Antimicrob. Chemother. 64(1), 1-4 (2009).
58. Mugnaini C, Pasquini S, Corelli F. The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry. Curr. Med. Chem. 16(14), 1746-1767 (2009).
59. Krebs A, Ludwig V, Boden O, Gobel MW. Targeting the HIV trans-activation responsive region-approaches towards RNA-binding drugs. Chembiochem 4(10), 972-978 (2003).
60. Hermann T, Tor Y. RNA as target for small-molecule therapeutics. Expert Opin. Ther. Patents 15(1), 49-62 (2005).
61. Baba M. Inhibitors of HIV-1 gene expression and transcription. Curr. Top. Med. Chem. 4(9), 871-882 (2004).
62. Richter SN, Palu G. Inhibitors of HIV-1 Tat-mediated transactivation. Curr. Med. Chem. 13(11), 1305-1315 (2006).
63. Yang M. Discoveries of Tat-TAR interaction inhibitors for HIV-1. Curr. Drug Targets Infect. Disord. 5(4), 433-444 (2005).
64. Mei H-Y, Galan AA, Halim NS et al. Inhibition of an HIV-1 Tat-derived peptide binding to TAR RNA by aminoglycoside antibiotics. Bioorg. Med. Chem. Lett. 5(22), 2755-2760 (1995).
65. Wang S, Huber PW, Cui M, Czarnik AW, Mei HY. Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism. Biochemistry 37(16), 5549-5557 (1998).
66. Bailly C, Colson P, Houssier C, Hamy F. The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism. Nucleic Acids Res. 24(8), 1460-1464 (1996).
67. Dassonneville L, Hamy F, Colson P, Houssier C, Bailly C. Binding of Hoechst 33258 to the TAR RNA of HIV-1. Recognition of a pyrimidine bulge-dependent structure. Nucleic Acids Res. 25(22), 4487-4492 (1997).
68. Hamy F, Brondani V, Florsheimer A, Stark W, Blommers MJ, Klimkait T. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. Biochemistry 37(15), 5086-5095 (1998).
69. Lind KE, Du Z, Fujinaga K, Peterlin BM, James TL. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem. Biol. 9(2), 185-193 (2002).
70. Mayer M, Lang PT, Gerber S et al. Synthesis and testing of a focused phenothiazine library for binding to HIV-1 TAR RNA. Chem. Biol. 13(9), 993-1000 (2006).
71. Hwang S, Tamilarasu N, Kibler K et al. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J. Biol. Chem. 278(40), 39092-39103 (2003).
72. Murchie AI, Davis B, Isel C et al. Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA. J. Mol. Biol. 336(3), 625-638 (2004).
73. Gatto B, Tabarrini O, Massari S et al. 2-phenylquinolones as inhibitors of the HIV-1 Tat-TAR interaction. ChemMedChem 4(6), 935-938 (2009).
74. Yuan D, He M, Pang R, Lin S, Li Z, Yang M. The design, synthesis and biological evaluation of novel substituted purines as HIV-1 Tat-TAR inhibitors. Bioorg. Med. Chem. 15(1), 265-272 (2007).
75. Davidson A, Leeper TC, Athanassiou Z et al. Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. Proc. Natl Acad. Sci. USA 106(29), 11931-11936 (2009).
76. Schang LM. First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy. Expert. Rev. Anti Infect. Ther. 4(6), 953-956 (2006).
77. Klebl BM, Choidas A. CDK9/cyclin T1: a host cellular target for antiretroviral therapy. Future Virol. 1(3), 317-330 (2006).
78. Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol. Sci. 29(6), 302-313 (2008).
79. Pumfery A, de la Fuente C, Berro R, Nekhai S, Kashanchi F, Chao SH. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr. Pharm. Des. 12(16), 1949-1961 (2006).
80. Schang LM, St Vincent MR, Lacasse JJ. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir. Chem. Chemother. 17(6), 293-320 (2006).
81. Schang LM. Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. Curr. Drug Targets Infect. Disord. 5(1), 29-37 (2005).
82. Wang Y, Liu XY, De Clercq E. Role of the HIV-1 positive elongation factor P-TEFb and inhibitors thereof. Mini Rev. Med. Chem. 9(3), 379-385 (2009).
83. Fisher PM. Cyclin-dependent kinase inhibitors: discovery, development and target rationale for different therapeutic applications. 30(9), 911-929 (2005).
84. Mancebo HS, Lee G, Flygare J et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 11(20), 2633-2644 (1997).
85. Chao SH, Fujinaga K, Marion JE et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275(37), 28345-28348 (2000).
86. Biglione S, Byers SA, Price JP et al. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 4, 47 (2007).
87. Ali A, Ghosh A, Nathans RS, et al. Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. Chembiochem 10(12), 2072-2080 (2009).
88. Wang D, de la Fuente C, Santiago F et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75(16), 7266-7279 (2001).
89. A gbot ta h E , de La Fuente C , Nek ha i S et al. Antiviral activity of CYC202 in HIV-1-infected cells. J. Biol. Chem. 280(4), 3029-3042 (2005).
90. Heredia A, Davis C, Bamba D et al. Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 19(18), 2087-2095 (2005).
91. Wang X, Yamataka K, Okamoto M, Ikeda S, Baba M. Potent and selective inhibition of Tat-dependent HIV-1 replication in chronically infected cells by a novel naphthalene derivative JTK-101. Antivir. Chem. Chemother. 18(4), 201-211 (2007).
92. Baba M, Okamoto M, Kawamura M et al. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol. 53(6), 1097-1103 (1998).
93. Witvrouw M, Daelemans D, Pannecouque C et al. Broad spectrum antiviral activity and mechanism of antiviral action of fluoroquinolone derivative K-12. Antiviral Chem. Chemother. 9(5), 403-411 (1998).
94. Okamoto M, Okamoto T, Baba M. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells. Antimicrob. Agents Chemother. 43(3), 492-497 (1999). (Pubitemid 29109508)
95. Okamoto H, Cujec TP, Okamoto M, Peterlin MB, Baba M, Okamoto T. Inhibition of the RNA-dependent transactivation and replication of the human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 272(2), 402-408 (2000).
96. Wang X, Miyake H, Okamoto M et al. Inhibition of the tax-dependent human T-lymphotropic virus type I replication in persistently infected cells by the fluoroquinolone derivative K-37. Mol. Pharmacol. 61(6), 1359-1365 (2002).
97. Kashiwase H, Momota K, Ohmine T et al. A new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus type 1 replication. Chemotherapy 45(1), 48-55 (1999).
98. Shi M, Wang X, Okamoto M, Takao S, Baba M. Inhibition of porcine endogenous retrovirus (PERV) replication by HIV-1 gene expression inhibitors. Antiviral Res. 83(2), 201-204 (2009).
99. Radl S, Bouzard D. Recent advances in the synthesis of antibacterial quinolones. Heterocycles 34(11), 2143-2177 (1992).
100. Gould RJ, Jacobs WA. The synthesis of certain substituted quinolones and 5,6-benzoquinolines. J. Am. Chem. Soc. 61(10), 2890-2895 (1939).
101. Grohe K, Heitzer H. Cycloaracylation of enamines, I. Synthesis of 4-quinolone-3-carboxylic acids. Liebigs Ann. Chem. 1987(1), 29-37 (1987).
102. Grohe K. The omportance of the cycloaracylation process for the synthesis of modern fluoroquinolones. Prakt. Chem. 335(5), 397-409 (1993).
103. Bayer AG [DE]: EP-612731-A1 (1994).
104. Ube Industries: EP-572259-A1 (1993).
105. Bayer AG [DE]: EP-422485-A2 (1991).
106. Bayer AG [DE]: US5300643 (1994).
107. Bayer AG [DE]: US5300643 (1994).
108. Bayer AG [DE]: WO9602540 (1996).
109. Bayer AG [DE]: WO9602532 (1996).
110. Bayer AG [DE]: WO9602533 (1996).
111. Bayer AG [DE]: WO9602511 (1996).